Maplight Therapeutics (NASDAQ:MPLT) Insider James Woodruff Lillie Sells 11,095 Shares

Maplight Therapeutics, Inc. (NASDAQ:MPLT) insider James Woodruff Lillie sold 11,095 shares of Maplight Therapeutics stock in a transaction that occurred on Tuesday, May 5th. The stock was sold at an average price of $28.20, for a total transaction of $312,879.00. Following the transaction, the insider directly owned 268,261 shares in the company, valued at $7,564,960.20. The trade was a 3.97% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

James Woodruff Lillie also recently made the following trade(s):

• On Wednesday, May 6th, James Woodruff Lillie sold 24,811 shares of Maplight Therapeutics stock. The stock was sold at an average price of $28.76, for a total transaction of $713,564.36.
• On Monday, May 4th, James Woodruff Lillie sold 15,801 shares of Maplight Therapeutics stock. The shares were sold at an average price of $27.96, for a total transaction of $441,795.96.

Maplight Therapeutics Stock Performance

Shares of MPLT opened at $29.04 on Thursday. Maplight Therapeutics, Inc. has a twelve month low of $12.24 and a twelve month high of $33.28. The firm has a 50 day moving average of $22.60. The company has a market capitalization of $1.24 billion and a price-to-earnings ratio of -0.73.

Maplight Therapeutics (NASDAQ:MPLT) last announced its quarterly earnings results on Thursday, March 26th. The company reported ($2.47) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.05) by ($1.42). As a group, research analysts forecast that Maplight Therapeutics, Inc. will post -3.96 EPS for the current year.

Key Maplight Therapeutics News

Here are the key news stories impacting Maplight Therapeutics this week:

• Positive Sentiment: HC Wainwright opened/updated coverage and issued detailed quarterly and FY estimates alongside a Buy rating and a $45 price target (implies ~55% upside from the recent price); the report provides a near‑term analyst catalyst and a bullish valuation anchor. HC Wainwright coverage (MarketBeat)
• Positive Sentiment: Needham reaffirmed its Buy rating on MPLT, reinforcing sell‑side support that can sustain buying interest. Needham reaffirmation (The Globe and Mail)
• Neutral Sentiment: Morningstar quote/coverage appears in the tape (useful for tracking consensus/third‑party data) but contains no new fundamental update by itself. Morningstar MPLT quote
• Negative Sentiment: Significant insider selling reported May 4–6: CEO Christopher Kroeger sold multiple blocks (~23,701 shares on May 6 and earlier sales), CFO Vishwas Setia, and insiders James W. Lillie and Erin P. Foff also sold material stakes. These transactions reduce insider holdings and may add near‑term supply pressure, though each sale was made under pre‑arranged Rule 10b5‑1 plans (which weakens the signal that sales reflect new negative company information). See CEO Form 4 filing. CEO Form 4 (SEC)
• Negative Sentiment: Additional insider Form 4 filings for James W. Lillie and Erin P. Foff confirm multi‑day sales at similar prices (May 4–6). Investors should monitor total sold vs. remaining insider ownership and trading volume to gauge impact. James W. Lillie Form 4 (SEC)

Institutional Trading of Maplight Therapeutics

A number of hedge funds and other institutional investors have recently made changes to their positions in the business. Strs Ohio acquired a new position in Maplight Therapeutics during the fourth quarter worth $53,000. Police & Firemen s Retirement System of New Jersey bought a new stake in Maplight Therapeutics during the fourth quarter worth $70,000. New York State Common Retirement Fund bought a new stake in Maplight Therapeutics during the fourth quarter worth $93,000. MetLife Investment Management LLC bought a new stake in Maplight Therapeutics during the fourth quarter worth $172,000. Finally, Walleye Capital LLC bought a new stake in Maplight Therapeutics during the fourth quarter worth $205,000.

Analyst Upgrades and Downgrades

A number of research analysts have weighed in on MPLT shares. Canaccord Genuity Group started coverage on shares of Maplight Therapeutics in a research note on Thursday, March 19th. They issued a “buy” rating and a $35.00 price target on the stock. Weiss Ratings assumed coverage on shares of Maplight Therapeutics in a report on Thursday, January 22nd. They issued a “sell (e)” rating on the stock. Wall Street Zen downgraded shares of Maplight Therapeutics from a “hold” rating to a “sell” rating in a report on Saturday, March 21st. HC Wainwright assumed coverage on shares of Maplight Therapeutics in a report on Monday. They issued a “buy” rating and a $45.00 price objective on the stock. Finally, Needham & Company LLC assumed coverage on shares of Maplight Therapeutics in a report on Wednesday, April 8th. They issued a “buy” rating and a $37.00 price objective on the stock. One research analyst has rated the stock with a Strong Buy rating, seven have given a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average price target of $34.43.

Maplight Therapeutics Company Profile

We are a clinical-stage biopharmaceutical company focused on improving the lives of patients suffering from debilitating central nervous system, or CNS, disorders. We were founded by globally recognized leaders in psychiatry and neuroscience research to address the lack of circuit-specific pharmacotherapies available for patients. Our discovery platform holds the potential to fill this void by identifying neural circuits causally linked to disease and targeting those circuits for therapeutic modulation.